Advances in Hematology

Review Article

The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma

Table 4

Rituximab-based salvage therapy in rituximab-naïve relapsing/refractory DLBCLs.


Author	Year		Pathological phenotype	DLCL (%)	Therapy	Conditioning regimen	PFS/EFS (%)		OS (%)

Kewalramani [36]	2004	36 147	WHO	100	R-ICE ICE	*	2y: 54 2y: 43	N.S.	2y: 67 2y: 56	N.S.

Sienawski [37]	2007	19 19	WHO	80	R-DHAP¹ DHAP¹	BEAM	2y: 57 2y: 18	0.0051	2y: 77 2y: 37	0.0051

Vallenga [38]	2008	113 112	WHO	80.5 78.6	R-DHAP-VIM-DHAP¹ DHAP-VIM-DHAP¹	BEAM	2y: 52 2y: 31	0.002	2y: 59 2y: 52	N.S.

Mounier [39]	2011	470	WHO	100	N.R.	BEAM and others^#	5y: 48	0.001**	5y: 63	N.R.

¹Plus radiotherapy at bulky disease.
*The choice of conditioning regimen depended on the patient’s age, the extent of previous therapy and the clinical trials active at the time of transplantation (see [30]).
^#See [39].
**Each patient was assessed as his or her own control.
WHO: World Health Organization classification of NHL; R: rituximab; ICE: ifosfamide, carboplatin, and etoposide; DHAP: cisplatin, cytarabine, and dexamethasone; VIM: etoposide, ifosfamide, and methotrexate; BEAM: carmustine, etoposide, cytarabine, and melphalan; N.R.: not reported; N.S.: not significant.